Stocks
Novo Nordisk A/SNVO
NYSEHealthcarePharmaceuticals$37.96-0.16%
A Denmark-based pharmaceutical manufacturer focused on diabetes care, obesity treatments, and other chronic diseases, with a portfolio anchored by insulin products and GLP-1 therapies such as Ozempic and Wegovy. The company generates the majority of its revenue from treatments for diabetes and weight management, making it a central player in the rapidly expanding metabolic disease market. Investors closely monitor prescription growth, pricing dynamics, and clinical pipeline developments given the outsized earnings impact of its obesity franchise.
Market Cap: $168.7B52W Range: $35.85 – $82.57
Congressional Interest in Novo Nordisk A/S (NVO)
3 members of Congress have disclosed 32 trades in Novo Nordisk A/S (NVO), a Healthcare company. The buy/sell breakdown shows 21 purchases versus 11 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
32
Unique Politicians
3
Buys
21
Sells
11
Who in Congress Is Trading NVO?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2010-05-02 | MICHAEL T. MCCAUL | sell | $1K – $15K |
| 2010-05-02 | MICHAEL T. MCCAUL | buy | $1K – $15K |